Aligos Therapeutics (ALGS) Payables (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Payables for 8 consecutive years, with $6.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 63.35% year-over-year to $6.4 million; the trailing twelve-month figure through Jun 2026 stood at $6.4 million (up 63.35% YoY), and the FY2025 full-year result was $4.0 million, up 54.88% from the prior year.
• Payables retreated to $6.4 million in Q2 2026 per ALGS's latest filing, from $7.6 million in the prior quarter.
• Across five years, Payables topped out at $7.6 million in Q1 2026 and bottomed at $2.5 million in Q4 2023.
• Historically, Payables has averaged $4.0 million across 5 years, with a median of $3.5 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Payables plunged 46.87% in 2023, then soared 110.4% in 2024.
• Over 5 years, Payables stood at $4.7 million in 2022, then slumped by 46.87% to $2.5 million in 2023, then increased by 2.15% to $2.6 million in 2024, then surged by 54.88% to $4.0 million in 2025, then soared by 61.5% to $6.4 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $6.4 million, $7.6 million, and $4.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.